Net Cash Provided by (Used in) Financing Activities in USD of Intellia Therapeutics, Inc. from 2016 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Intellia Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to Q1 2025.
  • Intellia Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $0.000, a 100% decline year-over-year.
  • Intellia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $186M, a 42.5% increase from 2023.
  • Intellia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $130M, a 77.6% decline from 2022.
  • Intellia Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $583M, a 20.9% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Intellia Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $0 -$60M -100% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q1 2024 $60M +$57.8M +2601% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q1 2023 $2.22M -$45.1M -95.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $47.3M -$11.3M -19.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $58.6M +$53.7M +1105% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $4.86M +$865K +21.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $4M -$2.72M -40.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $6.72M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02

Intellia Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $186M +$55.4M +42.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $130M -$453M -77.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $583M -$154M -20.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $737M +$365M +98.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $372M +$295M +386% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $76.4M +$36.2M +90.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $40.2M -$103M -71.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $143M -$24.3M -14.5% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 $167M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.